ESMO 2025 insights | Cromos Pharma
ESMO 2025: Notes From the Floor — What Will Really Change Oncology in 2026 By Vlad Bogin, MD, FACP, CEO, Cromos Pharma The 2025 ESMO Congress, held in Berlin, brought together over 35,000 oncology professionals from around the world to showcase data that are already reshaping the clinical landscape. Below are the readouts I think will actually change clinical practice and influence the way sponsors design trials in 2026 Read more
From Oysters to Orthopedics: China’s “Bone-02” Bio-Glue Redefines Fracture Repair Researchers at Zhejiang University’s Sir Run Run Shaw Hospital have unveiled Bone-02, a biomimetic “bone glue” capable of repairing complex fractures in just three minutes. The innovation was inspired by oysters’ remarkable ability to adhere to rocks underwater — a challenge long considered impossible to replicate in human physiology. How it works Unlike metal plates Read more
CRO Regulatory Affairs: Bridging Strategy, Compliance, and Speed Bringing a new therapy to patients is as much a regulatory journey as it is a scientific one. Every submission, meeting, and document must align perfectly with evolving international standards — from FDA INDs and NDAs to EMA CTIS, IMPDs, and the EU CTR framework. At Cromos Pharma, we view regulatory affairs not as an Read more
Clinical Research Focus. 45th Edition Trump Administration Weighs “Severe Restrictions” on U.S. Drug Licensing from China According to a New York Times report, the Trump administration is considering a draft executive order that would impose stricter oversight on U.S. pharmaceutical deals with Chinese biotech firms, including national security reviews of licensing agreements and tougher scrutiny of Chinese clinical trial data Read more

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us